Literature DB >> 23340475

Imaging of TKI-target interactions for personalized cancer therapy.

A J Poot1, P Slobbe, N H Hendrikse, A D Windhorst, G A M S van Dongen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23340475     DOI： 10.1038/clpt.2012.242

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  7 in total

1.  Pretreatment With Rifampicin and Tyrosine Kinase Inhibitor Dasatinib Potentiates the Inhibitory Effects Toward OATP1B1- and OATP1B3-Mediated Transport.

Authors:  Sonia Pahwa; Khondoker Alam; Alexandra Crowe; Taleah Farasyn; Sibylle Neuhoff; Oliver Hatley; Kai Ding; Wei Yue
Journal:  J Pharm Sci       Date:  2017-04-01       Impact factor: 3.534

2.  Assessing OATP1B1- and OATP1B3-Mediated Drug-Drug Interaction Potential of Vemurafenib Using R-Value and Physiologically-Based Pharmacokinetic Models.

Authors:  Ruhul Kayesh; Taleah Farasyn; Alexandra Crowe; Qiang Liu; Sonia Pahwa; Khondoker Alam; Sibylle Neuhoff; Oliver Hatley; Kai Ding; Wei Yue
Journal:  J Pharm Sci       Date:  2020-06-23       Impact factor: 3.534

Review 3.  Using positron emission tomography to study transporter-mediated drug-drug interactions in tissues.

Authors:  B Wulkersdorfer; T Wanek; M Bauer; M Zeitlinger; M Müller; O Langer
Journal:  Clin Pharmacol Ther       Date:  2014-03-28       Impact factor: 6.875

4.  A comparative PET imaging study with the reversible and irreversible EGFR tyrosine kinase inhibitors [(11)C]erlotinib and [(18)F]afatinib in lung cancer-bearing mice.

Authors:  Paul Slobbe; Albert D Windhorst; Marijke Stigter-van Walsum; Egbert F Smit; Heiko G Niessen; Flavio Solca; Gerd Stehle; Guus A M S van Dongen; Alex J Poot
Journal:  EJNMMI Res       Date:  2015-03-20       Impact factor: 3.138

5.  Development of [11C]vemurafenib employing a carbon-11 carbonylative Stille coupling and preliminary evaluation in mice bearing melanoma tumor xenografts.

Authors:  Paul Slobbe; Albert D Windhorst; Kevin Adamzek; Marije Bolijn; Robert C Schuit; Daniëlle A M Heideman; Guus A M S van Dongen; Alex J Poot
Journal:  Oncotarget       Date:  2017-06-13

Review 6.  Why are we failing to implement imaging studies with radiolabelled new molecular entities in early oncology drug development?

Authors:  Azeem Saleem; Philip Murphy; Christophe Plisson; Michael Lahn
Journal:  ScientificWorldJournal       Date:  2014-08-18

7.  Interactions of ABCG2 (BCRP) with epidermal growth factor receptor kinase inhibitors developed for molecular imaging.

Authors:  Israa Qawasmi; Miriam Shmuel; Sara Eyal
Journal:  Front Pharmacol       Date:  2014-11-21       Impact factor: 5.810
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.